证券日报网讯1月21日，莱美药业（300006）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东户数为30275户。 ...

Group 1 - The core viewpoint of the news is that Lai Mei Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.05% to 4.97 CNY per share, while the company has experienced a year-to-date decline of 3.31% [1] - As of January 9, the number of shareholders for Lai Mei Pharmaceutical increased by 4.40% to 30,700, while the average number of circulating shares per person decreased by 4.21% to 34,403 shares [2] - The company reported a revenue of 581 million CNY for the period from January to September 2025, reflecting a year-on-year decrease of 4.06%, and a net profit attributable to the parent company of -45.92 million CNY, down 73.82% year-on-year [2] Group 2 - Lai Mei Pharmaceutical has a total market capitalization of 5.248 billion CNY, with a trading volume of 84.09 million CNY and a turnover rate of 1.64% [1] - The company's main business segments include specialty drugs (38.24%), large-volume injections (26.27%), and other categories (21.89%), with anti-infection drugs contributing 10.10% and pharmaceutical sales services at 2.31% [1] - Since its A-share listing, Lai Mei Pharmaceutical has distributed a total of 280 million CNY in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - Laimei Pharmaceutical has established a joint investment with AglaeaPharma to create a multi-target small molecule drug screening platform and an early disease detection and diagnostic technology development platform [1] Group 1 - The company has set up a new entity called Guangxi Aglaea, in collaboration with AglaeaPharma [1] - AglaeaPharma's project platform has developed multiple technical platforms, product pipelines, and a series of products [1] - The initiative aims to form a globally integrated innovative research and development system [1] Group 2 - The company will continue to monitor the project's progress and fulfill its information disclosure obligations in a timely manner [1]

Group 1 - The core point of the article is that Laimei Pharmaceutical (300006) reported its shareholder count as of January 9, 2026, which stands at 30,689 households [1]

Group 1 - The A-share market continues to show strength in innovative drug concept stocks, with notable gains from companies such as Bibot-U nearing the daily limit and reaching a new high, and Yuandong Bio rising over 9% [1] - The National Medical Products Administration (NMPA) is set to support the "China debut" of innovative drugs, with plans to implement a data protection system for drug trials and establish exclusive market periods for pediatric and rare disease medications by 2026 [1] - The NMPA has announced further optimization of the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients [1] Group 2 - Notable stock performances include Bibot-U with a 19.95% increase, Yuandong Bio up 9.33%, and Hongbo Pharmaceutical rising 8.16%, among others [2] - The total market capitalization for Bibot-U is 22.3 billion, while Yuandong Bio stands at 11.5 billion, and Hongbo Pharmaceutical at 4.867 billion [2] - Year-to-date performance shows Bibot-U leading with a 70.89% increase, followed by Hongbo Pharmaceutical at 16.74% and Lai Mei Pharmaceutical at 7.59% [2]

证券代码：300006 证券简称：莱美药业 公告编号：2026-001 重庆莱美药业股份有限公司 关于控股子公司诉讼事项达成和解的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.案件所处的诉讼阶段：处于执行阶段，相关方达成和解； 2.所处的当事人地位：原告； 3.对公司损益产生的影响：根据协议安排，耀匀医药已投入款项中 6,931,809.42 元归成都金星所有，不再返还；耀匀医药已划走未归还的 7,068,190.58 元归耀匀医药所有，亦不再退还。本次和解有助于稳定子公司经 营，不会对公司本期利润产生重大不利影响，不存在损害公司及股东利益的 情形。 丙方：德国沙奴姆.凯贝克股份有限责任公司 丁方：成都金星健康药业有限公司（以下简称"目标公司"） 一、本次和解事项涉及诉讼的基本情况 重庆莱美药业股份有限公司（以下简称"公司"）及控股子公司成都金 星健康药业有限公司（以下简称"成都金星"）前期与其少数股东 Sanum Kehlbeck GmbH&Co.KG（德国沙奴姆.凯贝克股份有限责任公司）、成都耀匀 医药科技有限公司（以下简称"耀 ...

莱美药业公告称，控股子公司成都金星与耀匀医药等的诉讼处于执行阶段并达成和解。2025年各方签署 《成都金星健康药业有限公司增资和认购协议之补充协议》，一致同意解除原协议。耀匀医药已投入的 1400万元中，693.18万元归成都金星，706.82万元归耀匀医药，双方不再互相主张返还。待产品恢复产 销，耀匀医药可优先获部分区域省级销售代理权。本次和解有助于稳定子公司经营，对本期利润无重大 不利影响。此外，公司及子公司还有5起小额诉讼仲裁，涉资约300.80万元，占最近一期经审计净资产 的0.16%。 ...

Group 1 - The core point of the article is that Laimei Pharmaceutical (SZ 300006) held its 49th board meeting on December 29, 2025, via telecommunication to discuss the performance assessment plan for the leadership team in 2024 [1] - For the year 2024, Laimei Pharmaceutical's revenue composition is as follows: 84.09% from pharmaceutical manufacturing, 13.06% from pharmaceutical distribution, 1.64% from other businesses, and 1.21% from service income [1] - As of the report date, Laimei Pharmaceutical has a market capitalization of 5.6 billion yuan [1] Group 2 - The article also mentions a significant event involving Moutai distributors, where over 2,000 attendees gathered for a conference to discuss major changes related to Moutai's pricing and distribution strategies [1] - Chairman Chen Hua emphasized that distributors can no longer rely on passive income [1]

证券代码：300006 证券简称：莱美药业 公告编号：2025-060 重庆莱美药业股份有限公司 第五届董事会第四十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重庆莱美药业股份有限公司（以下简称"公司"）董事会办公室于 2025 年 12 月 24 日以通讯方式向全体董事送达召开第五届董事会第四十九次会议 的通知。本次会议于 2025 年 12 月 29 日以通讯表决方式召开。本次会议应出 席董事 9 名，实际出席董事 9 名。本次会议的召集、召开符合《中华人民共 和国公司法》《公司章程》及有关法律法规的规定。本次会议由公司董事长 梁建生先生主持。经公司出席会议董事审议和逐项书面表决，形成了以下决 议： 一、审议通过了《关于制定<重庆莱美药业股份有限公司融资管理制度>的 议案》 1、第五届董事会第四十九次会议决议。 特此公告。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、审议通过了《关于制定<重庆莱美药业股份有限公司融资担保管理办法> 的议案》 董事会同意制定《重庆莱美药业股份有限公司融资担保管理办法》。 表决结果：同意 9 ...

Core Viewpoint - The announcement by Chongqing Laimei Pharmaceutical Co., Ltd. indicates that major shareholder Qiu Yu will passively reduce his shareholding due to overdue debts related to a pledged securities repurchase agreement with Guohai Securities, but this will not affect the company's control or ongoing operations [1][4]. Group 1: Shareholding and Reduction Plan - As of the disclosure date, Qiu Yu holds 110,700,054 shares of Laimei Pharmaceutical, accounting for 10.48% of the total share capital [2]. - The reduction involves the forced sale of 54 shares through centralized bidding, with a reduction period of three months from the announcement date, and a limit of 1% of the total shares within any consecutive 90 days [2]. - The shares being reduced were originally held before the company's IPO, subscribed during a major asset restructuring in 2013, and include shares from historical equity distributions [2]. Group 2: Compliance and Background - The shares subject to reduction were pledged in a repurchase agreement as early as August 23, 2017, and the pledge registration was completed by August 27, 2023 [3]. - Laimei Pharmaceutical emphasizes that the passive reduction complies with relevant regulations and does not involve any violations [3]. Group 3: Impact on Company - The company asserts that the reduction will not lead to a change in control, as Qiu Yu has delegated voting rights to Zhongheng Group, which will maintain the governance structure [4]. - Even if the reduced shares are acquired by third parties, it will only affect the voting rights held by Zhongheng Group without altering the company's controlling shareholder [4]. - The company will monitor the reduction process and fulfill disclosure obligations as required [4].